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Perivascular adipose tissue exerts an anticontractile inﬂuence on vascular smooth muscle. This study was conducted to determine
whetherperiureteraladiposetissue(PUAT)couldexertasimilarinﬂuenceuponureteralsmoothmuscle.Acetylcholine-stimulated
(10−7 M–10−4 M) contractile responses of ureteral segments obtained from male Wistar rats were recorded in the presence and
absence of PUAT. Ureters with PUAT generated phasic contractile responses with signiﬁcantly lower frequencies (P<0.001) and
magnitudes(P<0.001)comparedwithuretersclearedoftheirperiureteraladiposetissue.RemovalofPUATsigniﬁcantlyincreased
the frequency (P<0.01) and magnitude (P<0.01) of the contractile responses. Bioassay experiments demonstrated that ureters
with PUAT released a transferable factor that signiﬁcantly reduced frequencies (P<0.05), but not magnitudes, of the contractile
responses of ureters cleared of PUAT. The nitric oxide synthase inhibitor L-NNA (10−4 M) did not signiﬁcantly inﬂuence the
anticontractile eﬀect exerted by ureters with PUAT. This is the ﬁrst study to demonstrate that ureteral motility is inﬂuenced by its
surrounding adipose tissue. The PUAT has an anticontractile eﬀect which is mediated by a transferable factor released from the
PUAT. The identity of the factor is unknown but does not exert its eﬀect through nitric oxide.
1.Introduction
Adipose tissue was once recognised as only having protective
and thermal functions, but it is now characterised as an
endocrine organ mediating its paracrine eﬀects on neigh-
bouring tissues through lipid and protein mediators known
as adipokines [1]. It has recently been demonstrated that
vascular smooth muscle is inﬂuenced by its surrounding
adipose tissue. Speciﬁcally, the perivascular adipose tissue
(PVAT) exerts an anticontractile eﬀect on the vasculature.
Rat mesenteric arteries [2, 3] and human subcutaneous
arteries [4] with intact PVAT display diminished contractile
responses in comparison with those cleared of PVAT. Similar
results have been observed in rat aortic ring preparations
where it was identiﬁed that a transferable factor originating
from the adipose tissue is responsible for the eﬀect [5]. The
transferable factor mediates its eﬀects in an endothelium-
dependent and- independent fashion [5]. Cultured endothe-
lial cells generate nitric oxide (NO) in response to medium
conditioned by PVAT [5] and NOS inhibition attenuates
the anticontractile activity [4]. Adiponectin has emerged as
acandidateforthePVAT-derivedanticontractilefactor[4,6].
Unlike other adipokines, adiponectin expression is restricted
to the adipocyte cells of adipose tissue [7].
To date, investigations into the anticontractile eﬀect
of adipose tissue have been conﬁned to vascular smooth
muscle preparations. In the present study the question of
whether the periureteral adipose tissue (PUAT) exerts an
anticontractile eﬀect on ureteral smooth muscle, in a similar
fashion to the eﬀect of PVAT on vascular smooth muscle, has
been addressed. The study was therefore designed to test the
hypothesis that PUAT attenuates ureteral motility.
2. Methods
Male Wistar rats with body weights ranging from 241 to
531g were used in this study. They were housed at the
Biomedical Facility, University College Dublin, where they
were maintained on standard rat chow and tap water ad
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Rats were humanely killed by stunning and cervical
dislocation. Both ureters were removed immediately and
placed into a petri dish containing PSS of the follow-
ing composition (mM): NaCl 119, KCl 4.7, NaHCO3 25,
KH2PO4 1.18, MgSO4 1.17, K2-EDTA 0.026, D(+)-glucose
5.5, and CaCl2 1.6. Each ureter was noted as being either
left or right and tissue preparation commenced immediately.
Under a binocular microscope the surrounding adipose
tissue was carefully dissected free or it was left intact as
required. Segments of ureter 15mm in length were then
prepared for assessment of contractile function. Ureteral
segments were suspended in 20mL capacity water-jacketed
tissue baths containing PSS: one end was secured to a
tissue holder in the bath by means of cotton thread while
the other was secured to a force transducer in a similar
fashion. The baths were then warmed to 37◦C and gassed
with 5% CO2 in air. A pretension of 0.2g was applied to
facilitate maximal contractile responses in this preparation
(unpublished observations). Ureteral segments were allowed
to equilibrate under these conditions for 40 minutes before
the addition of any reagents.
2.1. Chemicals and Reagents. All chemicals and reagents
were obtained from Lennox Laboratory Supplies (Dublin,
Ireland). ACh was dissolved in deionised water (10−2 M),
divided into 1mL aliquots, and then stored frozen (−20◦C)
until required. Serial dilutions of the 10−2 M ACh stock
solution were made in PSS when required. L-NNA (10−2 M)
was prepared fresh each day as required in PSS.
2.2. Protocol 1: Inﬂuence of Periureteral Adipose Tissue. In
this protocol ureteral segments were used with PUAT intact
(n = 12) or dissected free (n = 12), with left or right
segments (both taken from the same rat) subject to PUAT
removal in alternate fashion. Each segment was suspended
in a separate tissue bath and force recordings were made
simultaneously. After the equilibration period acetylcholine
(ACh, 10−7−10−4 M) was applied in a cumulative fashion.
Each concentration was applied for four minutes. ACh was
the only agonist used in this and all subsequent protocols
because it consistently stimulates contractile responses;
unpublished observations in our laboratory have demon-
strated that adrenoceptor agonists such as noradrenaline and
phenylephrine do not.
2.3.Protocol2:Bioassay. Thisprotocolwasconductedimme-
diately after the washout at the end of protocol 1 and
utilised half of the PUAT-free ureters tested in protocol
1. The ureter with PUAT was removed from its bath and
then loosely suspended in the tissue bath that contained the
contralateral PUAT-free ureter and a further equilibration
for 40 minutes ensued. ACh-stimulated contractions of the
cleaned ureter were then recorded with an identical ACh
application protocol as described above.
2.4. Protocol 3: Time Control. The remaining clean ureters
(n = 6) following protocol 1 were used. Following washout
of the ACh a second 40 minute period elapsed prior to a
repeat of the ACh challenge.
2.5. Protocol 4: PUAT Removal. This protocol was applied to
PUAT intact ureters subsequent to completion of protocol 1
(n = 4) and to PUAT intact ureters following completion
of protocol 2 (n = 4). The ureter was removed from the
tissue bath and placed in a petri dish containing PSS. The
surroundingadiposetissuewasdissectedfreefromtheureter
under a binocular microscope and both ends of the ureter
were retied with thread. The ureter was resuspended in the
bath for a further 40 minutes equilibration period. ACh was
applied in the same manner as described above for protocol
1 and was therefore either the second or third challenge with
ACh.
2.6. Protocol 5. PUAT-free ureteral segments (n = 10) were
suspended in a tissue bath and challenged with ACh in an
identical fashion to that of protocol 1. The contralateral
ureter with PUAT intact was then loosely suspended in the
same tissue bath as the PUAT-free ureteral segment. The
nitric oxide synthase inhibitor L-NNA (10−4 M) was applied
to the bath and, following a further 40 minute period the
ACh challenge was repeated. Left and right ureters were used
as PUAT-free segments in alternate fashion.
3.DataAnalysis
ACh responses were recorded using the AcqKnowledge data
acquisition software. Contractile responses were phasic in
nature and the responses in the last three minutes (i.e.,
stable responses) of each ACh application were used for
analysis purposes. Frequencies (min−1) and magnitudes
(g) were analysed. Concentration response curves were
analysed by means of repeated measures analysis of variance
(RMANOVA) using the SPSS statistical program. When sta-
tistically signiﬁcant diﬀerences were detected, the responses
at each concentration were compared between groups by
means of paired t-tests modiﬁed by the false discovery
rate procedure [8] to cater for multiple comparisons. Data
are presented as mean ± SEM throughout and diﬀerences
betweengroupswereconsideredstatisticallysigniﬁcantwhen
P<0.05.
4. Results
A sample original recording obtained in protocol 1 is shown
in Figure 1. ACh-stimulated contractile responses of PUAT
intactureteralsegmentsweresigniﬁcantlyreducedcompared
to those of PUAT-free ureters in terms of both frequency
(Figure 2) and magnitude (Figure 3). After equilibration in
the presence of a ureter with intact PUAT (protocol 2), the
frequencyofthePUAT-freeureteralcontractionsweresignif-
icantly reduced (Figure 4). Amplitudes of contraction were
also reduced but the eﬀect was not statistically signiﬁcant
(Figure 5).
Time control experiments (protocol 3) revealed that ACh
concentration response relationships were not signiﬁcantlyISRN Urology 3
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Figure 1: Sample recording of Ach-induced ureteral contraction.
ACh-induced contractile responses in a ureter with PUAT removed
(lower trace) were greater than those of the contralateral ureter +
PUAT (upper trace). ACh (10−5 M) was present and increased to
10−4 M at the time point indicated.
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Figure 2: Ureteral contractile responses to ACh in the presence
and absence of PUAT. Ureters + PUAT (open bars, n = 12) and
ureters with PUAT removed (closed bars, n = 12). Frequencies were
signiﬁcantly attenuated in the ureter + PUAT group (P<0.001
RMANOVA group term and group × concentration term). ∗P<
0.05, ∗∗∗P<0.001.
diﬀerent when two ACh challenges were separated by 40
minutes (Figures 6 and 7).
Removal of PUAT from ureteral segments (protocol 4)
signiﬁcantly increased the frequency (Figure 8)a n dm a g -
nitude (Figure 9) of contractile responses in all cases. In
the presence of L-NNA (protocol 5) the presence of PUAT
remained associated with reduced contractile frequencies
(Figure 10). Consistent with no signiﬁcant reduction in
contractile magnitude in the presence of PUAT in the
bioassay experiments (Figure 5), contractile magnitudes of
PUAT-free ureters were also not signiﬁcantly aﬀected by the
presence of PUAT plus L-NNA (Figure 11).
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Figure 3: Ureteral contractile responses to ACh in the presence
and absence of PUAT. Ureters + PUAT (open bars, n = 12) and
ureters with PUAT removed (closed bars, n = 12). Magnitudes were
signiﬁcantly attenuated in the ureter + PUAT group (P<0.001
RMANOVA group term and group × concentration term). ∗∗P<
0.01, ∗∗∗P<0.001.
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Figure 4: Inﬂuence of coincubation with PUAT on contractile
responses to ACh on PUAT-free ureters. Frequency of contractile
responses to ACh of ureters with PUAT removed in the absence
(closed bars, n = 6) and presence (open bars, n = 6) of ureters with
PUAT. Frequencies were signiﬁcantly attenuated in the presence
of a ureter + PUAT (P<0.05 RMANOVA group term; group ×
concentration term, P = 0.07). ∗P<0.05.
5. Discussion
The present study provides evidence for an adipose tissue
derived anticontractile eﬀect on ureteral motility. We have
demonstrated that periureteral adipose tissue (PUAT) has
an anticontractile eﬀect on ureteral smooth muscle which is
mediated by a transferable factor. The identity of that factor
is not known but it operates in a nitric oxide-independent
fashion to reduce the frequency of ureteral phasic contrac-
tions. We could not demonstrate that the factor acts in4 ISRN Urology
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Figure 5: Inﬂuence of coincubation with PUAT on contractile
responses to ACh on PUAT-free ureters. Magnitude of contractile
responses to ACh of ureters with PUAT removed in the absence
(closed bars, n = 6) and presence (open bars, n = 6) of ureters
with PUAT. Magnitudes were not signiﬁcantly diﬀerent.
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Figure 6: Inﬂuence of repetitive application of ACh on PUAT-free
ureteral contractile responses. There were no signiﬁcant diﬀerences
in frequency between the ﬁrst ACh challenge (closed bars, n = 6)
and the second ACh challenge (open bars, n = 6).
a transferable fashion to diminish the magnitude of contrac-
tile responses but removal of PUAT signiﬁcantly enhanced
the magnitude demonstrating that it has the capacity to at
leastactinaparacrinefashion.Accordingly,PUATnegatively
diminishes smooth muscle contractile function in a manner
similar to that described for perivascular adipose tissue
[2–5].
The transferable factor originating from perivascular
adipose tissue has been shown to mediate its anticon-
tractile eﬀects by endothelium-dependent and independent
means [5]. The endothelium-dependent relaxation mech-
anism involves the release of an adipose derived relaxing
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Figure 7: Inﬂuence of repetitive application of ACh on PUAT-free
ureteral contractile responses. There were no signiﬁcant diﬀerences
in magnitudes between the ﬁrst ACh challenge (closed bars, n = 6)
and the second ACh challenge (open bars, n = 6).
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Figure 8 :I n ﬂ u e n c eo fr e m o v a lo fP U A To nu r e t e r a lc o n t r a c t i l e
responses to ACh. Contraction frequencies were signiﬁcantly
increased (RMANOVA P<0.01 group term, P<0.05 group ×
concentration term) in the ureters following PUAT removal (closed
bars, n = 8) compared to those prior to PUAT removal (open bars,
n = 8). ∗P<0.05.
factor (ADRF) resulting in increased NO production in
the endothelium with subsequent K+ channel activation
and relaxation [5]. Voltage- [3]a n dC a 2+-dependent [5,
9]K + channels have been implicated in this regard. The
endothelium-independent relaxation mechanism involves
the generation of H2O2 within the adipose tissue withISRN Urology 5
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Figure 9 :I n ﬂ u e n c eo fr e m o v a lo fP U A To nu r e t e r a lc o n t r a c t i l e
responses to ACh. Contraction magnitudes were signiﬁcantly
increased (RMANOVA P<0.01 group term, P<0.05 group ×
concentration term) in the ureters following PUAT removal (closed
bars, n = 8) compared to those prior to PUAT removal (open bars,
n = 8). ∗P<0.05.
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Figure 10: Inﬂuence of coincubation with PUAT + L-NNA on
contractile responses to ACh of PUAT-free ureters. ACh stimulated
contractile frequencies of PUAT-free ureters remained signiﬁcantly
greater in the absence (control, closed bars, n = 10) than those
in the presence (open bars, n = 10) of a ureter + PUAT and L-
NNA. (RMANOVA P<0.05 group term, P<0.001 group ×
concentration term). ∗P<0.05, ∗∗P<0.01.
subsequent activation of soluble guanylyl cyclase and relax-
ation of the smooth muscle [5].
Adiponectin has been identiﬁed as the ADRF in human
small arteries, with the anticontractile eﬀect inhibited by
adiponectin type-1 receptor blocking peptide and the nitric
oxide synthase inhibitor L-NMMA [4]. In support of
this identiﬁcation adiponectin increases NO production in
M
a
g
n
i
t
u
d
e
 
(
g
)
Before ACh −7 −6 −5 −4
0
0.05
0.1
0.15
0.2
0.25
0.3
Log10 (acetylcholine, (M))
Figure 11: Inﬂuence of coincubation with PUAT + L-NNA on
contractile responses to ACh of PUAT-free ureters. ACh stimulated
contractilemagnitudesofPUAT-freeuretersintheabsence(control,
closed bars, n = 10) and presence (open bars, n = 10) of a ureter
+ PUAT and L-NNA. Contractile magnitudes were not signiﬁcantly
diﬀerent.
bovine aortic endothelial cells [6] and exogenous applica-
tion of adiponectin to rat mesenteric arteries results in a
vasodilatation [4]. Furthermore, adiponectin administration
ameliorates the hypertension exhibited by obese mice [10].
ThemechanismbywhichPUATmediatesitsanticontrac-
tile eﬀects has not been identiﬁed. The urothelium of rats
has been shown to generate NO [11]a n dL - N N Ah a sb e e n
demonstrated to inhibit porcine ureteral relaxations which
can be reversed by L-arginine [12]. Therefore, attempts were
made to determine whether NO mediates the anticontractile
eﬀect of PUAT in the present study. The application of L-
NNA was without eﬀect on ureteral contractile responses;
it did not prevent the reduction of contractile frequency
exerted by PUAT in bioassay experiments. This suggests
that the PUAT anticontractile eﬀect is not mediated by NO.
PUAT did not reduce the contractile magnitude in bioassay
experiments but the presence of an intact PUAT layer was
associatedwithareductioninthecontractilemagnitude.The
reasons for this discrepancy remain unclear. It is possible
that there was a higher local concentration of PUAT-derived
ADRF when it acted in a paracrine fashion upon ureteral
smooth muscle with an intact PUAT layer, while at the
lower concentrations expected in the bioassay medium it
has the capacity to diminish the frequency and not the
magnitude of the contractile response. Given that PUAT in
the bioassay experiments did not diminish the magnitude
of the contractile responses of PUAT-free ureters the lack of
an inhibitory eﬀect exerted by L-NNA upon magnitude is
not surprising. The absence of an inﬂuence of L-NNA upon
ureteral contractile responses in this study is consistent with
previous unpublished observations from our laboratory.
The apparent diﬀerence in the anticontractile mech-
anisms in the ureter and the vasculature may be due
to regional diﬀerences in adipose tissue function. It has6 ISRN Urology
been suggested that adipose depots in diﬀerent anatomical
locationsvaryinfunction;preadipocytecellcharacteristicsof
mesenteric adipose tissue diﬀer to those of omental adipose
tissue in several respects [13]. It has also been reported
that there are regional diﬀerences in adiponectin secretion
in human adipose tissue [14]. This latter observation may
explain the diﬀerence in the anticontractile mechanism
observed in the ureter compared to the vasculature but, as
yet, any suggested mechanism remains speculative. Adipose
tissue expresses a range of diﬀerent mediators such as
adrenomedullin, resistin, visfatin, leptin, IL-6, IL-8, and
MCP-1 [15], any of which could be a possible mediator of
this anticontractile eﬀect in the ureter. A further germane
consideration is the mode of contraction; ureteral smooth
muscle exhibits phasic contractile behaviour while that of
vascular smooth muscle is tonic in nature. Therefore the
possibility of diﬀerent sites of action for ADRF in diﬀerent
smooth muscle arises.
Recentstudiesonvascularsmoothmusclehavedescribed
other possible anticontractile mediators released from adi-
posetissue.Angiotensin-(1–7)(Ang-1–7)wasshowntobein
abundance in PVAT and has a clear anticontractile eﬀect on
rat aorta which was susceptible to NOS inhibition [9]. Ang-
(1–7) binds to Mas receptors on endothelial cells resulting
in the activation of endothelial NOS (eNOS) [16]. The
attenuation of contractions by Ang-(1–7) was demonstrated
in control mice but was absent in Mas receptor knockout
mice [17]. Palmitic acid methyl ester has also been described
as an ADRF [18].
The inﬂuence of adipose tissue on vascular smooth
muscle has been shown to be important in some pathophys-
iological conditions. The anticontractile eﬀect is decreased
in aortic preparations of spontaneously hypertensive rats
(SHR) [18, 19] and in hypoxia [4], increased in the aorta
of hyperglycemic rats [20], and abolished in human small
arteries in obesity [4]. Furthermore, nicotine exposure may
attenuate the anticontractile eﬀect [21]. The amount of
adiposetissuesurroundingthesmoothmusclemayalsobeof
importance [3, 22]. The physiological role of PUAT remains
to be established but it may be hypothesised that PUAT has
a role in the maintenance of ureter patency, especially during
times of increased intra-abdominal pressure. A role for
PUAT in the regulation of ureteral peristaltic rhythm in vivo
remains to be identiﬁed. However, it would be interesting
to determine whether abnormalities of PUAT anticontractile
eﬀects account for abnormal ureteric motility such as that of
vesicoureteral reﬂux.
In summary, the results from the present study demon-
strate for the ﬁrst time that PUAT negatively inﬂuences
ureteral motility. The anticontractile eﬀect is mediated by
a transferable factor that remains to be identiﬁed but its
activity is not accounted for by a nitric oxide dependent
mechanism.
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